Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-004740.pdf
0001179110-17-004740.rtf
0001179110-17-004740.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-004739.pdf
0001179110-17-004739.rtf
0001179110-17-004739.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-17-001502.pdf
0001558370-17-001502.rtf
0001558370-17-001502.xls
S-3ASR

S-3ASR

 View HTML
0001558370-17-001548.pdf
0001558370-17-001548.rtf
0001558370-17-001548.xls
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0001558370-17-001547.pdf
0001558370-17-001547.rtf
0001558370-17-001547.xls
EX-101.INS - EX-101.INS
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001558370-17-001552.pdf
0001558370-17-001552.rtf
0001558370-17-001552.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-17-005572.pdf
0000899243-17-005572.rtf
0000899243-17-005572.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-002766.pdf
0001179110-17-002766.rtf
0001179110-17-002766.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-002767.pdf
0001179110-17-002767.rtf
0001179110-17-002767.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-002768.pdf
0001179110-17-002768.rtf
0001179110-17-002768.xls